01.06.10
Indication: Colon cancer
Source: American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, December 2009.
Research: Participants in this study were aged 25 to 75 years and had already had one or more colorectal adenomas removed, but did not have any other diagnosis of colorectal diseases, cancer or life-threatening illnesses. Researchers from the National Institute for Cancer Research in Genoa, Italy randomized 411 participants to the placebo group or to receive an antioxidant compound—specifically selenomethionine (200 μg), zinc (30 mg), vitamin A (6000 IU), vitamin C (180 mg) and vitamin E (30 mg).
Results: Supplementation with a selenium-based antioxidant compound decreased the risk of developing new polyps of the large bowel by 40%. Also, the benefit observed after the conclusion of the trial persisted through 13 years of follow-up. Researchers are currently conducting a study to evaluate the role of genetic alterations as predictors of metachronous adenomas in participants who received the antioxidant compound.
Source: American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, December 2009.
Research: Participants in this study were aged 25 to 75 years and had already had one or more colorectal adenomas removed, but did not have any other diagnosis of colorectal diseases, cancer or life-threatening illnesses. Researchers from the National Institute for Cancer Research in Genoa, Italy randomized 411 participants to the placebo group or to receive an antioxidant compound—specifically selenomethionine (200 μg), zinc (30 mg), vitamin A (6000 IU), vitamin C (180 mg) and vitamin E (30 mg).
Results: Supplementation with a selenium-based antioxidant compound decreased the risk of developing new polyps of the large bowel by 40%. Also, the benefit observed after the conclusion of the trial persisted through 13 years of follow-up. Researchers are currently conducting a study to evaluate the role of genetic alterations as predictors of metachronous adenomas in participants who received the antioxidant compound.